VRTX Stock Price Today (July 2026) — Vertex Pharmaceuticals Incorporated Analysis & Key Metrics 2026-07-17
Vertex Pharmaceuticals Incorporated (VRTX) is trading at $485.65, down 0.08% today (as of July 2026). The stock continues to show sustained strength above key moving averages, attracting attention from investors looking for Healthcare growth opportunities.
- According to consensus analyst estimates, the 1-year price target is $548.69 (13.0% upside).
- Volatility remains elevated (30.87% annualized), implying wide price swings for short-term traders.
- The fundamental picture, based on the latest financial filings, is nuanced: solid revenue growth (7.80% YoY) alongside significant competitive pressures.
VRTX Stock Analysis: Key Metrics & Valuation (July 2026)
Concise, actionable data for investors
Vertex Pharmaceuticals Incorporated - Historical Price & Volume
Market Cap
Enterprise Value: $120.81B
P/E Ratio
Forward P/E: 23.22
Revenue Growth
Year over Year
Analyst Target
+13.0% upside potential
Key Investor Questions About VRTX
What investors need to know before buying
Based on current market data, VRTX presents a neutral technical setup with caution warranted fundamentals.
- Technicals say: Neutral (RSI 49.03)
- Fundamentals say: Caution warranted (high leverage concerns)
VRTX's growth trajectory depends on its ability to expand within the Biotechnology sector while managing margin pressures.
- Future growth will depend on performance in core Biotechnology operations.
- The ability to manage competitive pressures will be crucial for sustained growth.
The primary risks for VRTX investors include debt exposure and competitive dynamics in the Biotechnology industry.
- $1.99B in debt could be a headwind in a high-rate environment.
- Fierce competition from established players in Biotechnology.
52-Week Trading Range
Over the past year, VRTX stock traded between $362.50 and $507.92—recovering meaningfully from lows and currently near the higher end. Big swings are likely unless a major catalyst emerges.
Volatility & Risk Profile
With 30.87% annualized volatility and β=0.47, the stock exhibits low sensitivity to market moves—making VRTX suitable for investors comfortable with active risk management.
Institutional & Insider Ownership
High institutional backing, but elevated short interest signals a potential battleground stock.
Analyst Sentiment & Price Targets
Latest News & Headlines
Recent headlines and coverage
1 Nasdaq 100 Stock to Keep an Eye On and 2 We Question
The Nasdaq 100 (^NDX) is home to some of the biggest success stories in tech and growth investing. However, certain stocks in the index face challenges like profitability concerns, rising costs, or shifts in market trends.
Collect 9.8% On VRTX Stock Now, And Still Keep 15% Of Upside
Get paid a guaranteed income on your Vertex shares today, which you keep no matter what, for agreeing to sell them at a higher price if the stock keeps climbing.
Vertex Pharmaceuticals Incorporated (VRTX) Is a Trending Stock: Facts to Know Before Betting on It
Vertex (VRTX) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
IBB ETF Holds Fewer Bets Than You Think
An ETF's label tells you the category, but the real story is always in the portfolio's actual shape.
Vertex to Acquire Crinetics Pharmaceuticals (CRNX) in $85 Per Share Cash Deal
Crinetics Pharmaceuticals Inc. (NASDAQ:CRNX) is one of the 10 affordable biotech stocks to buy right now. On July 6, Crinetics Pharmaceuticals Inc. (NASDAQ:CRNX) and Vertex Pharmaceuticals announced that both companies have agreed to a definitive agreement, according to which Vertex will acquire Crinetics Pharmaceuticals. The deal is priced at $85 a share in cash consideration, […]
Here's Why Vertex Was Willing to Pay a Premium of More Than 100% for Crinetics Pharmaceuticals
Vertex's $10 billion acquisition may have spooked investors, given how rich it appeared to be.
Vertex Pharmaceuticals (VRTX) Declines More Than Market: Some Information for Investors
Vertex Pharmaceuticals (VRTX) reached $480.25 at the closing of the latest trading day, reflecting a -1.06% change compared to its last close.
Does Vertex's Acquisition of Crinetics Pharmaceuticals Make the Stock a No-Brainer Buy?
Vertex Pharmaceuticals recently announced its largest-ever acquisition.
What to Expect From Vertex Pharmaceuticals' Next Quarterly Earnings Report
Vertex Pharmaceuticals will release its second-quarter earnings next month, and analysts anticipate a single-digit bottom-line growth.
Vertex (VRTX) Wins FDA Expansion For CASGEVY And Advances ALYFTREK In Canada
Vertex Pharmaceuticals (NasdaqGS:VRTX) received expanded FDA approval for CASGEVY, extending use to children as young as 2 years with sickle cell disease and beta thalassemia. The company also signed a Letter of Intent with Canadian national payers that outlines commercial access terms for ALYFTREK, its next generation cystic fibrosis therapy. These updates arrive as Vertex Pharmaceuticals trades around $485.39 and remains closely watched after a 140.0% return over the past 5 years and a...
Frequently Asked Questions
Common investor questions about Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated (VRTX) is currently trading at $485.65. The RSI (14-day) is at 49.0, indicating neutral territory. Wall Street analysts have a consensus "buy" recommendation. The mean analyst price target of $548.69 implies 13.0% upside from current levels. Volatility is moderate at 30.9% annualized, meaning price movements are relatively contained. Investors should consider their risk tolerance, investment horizon, and portfolio diversification before making a decision.
Based on current valuation metrics for Vertex Pharmaceuticals Incorporated (VRTX): The trailing P/E ratio is 28.84, which is in line with broader market averages. The forward P/E is 23.22, lower than the trailing P/E, suggesting analysts expect earnings improvement. The PEG ratio is 1.84, near 1.0, suggesting roughly fair value relative to growth. Price-to-Book is 6.38. Price-to-Sales is 10.09. Valuation should be compared to Biotechnology industry peers for context, as different sectors trade at different multiples.
Based on 29 analysts covering VRTX, the consensus price target is $548.69. This represents a 13.0% upside from the current price of $485.65. The range spans from a low target of $330.00 to a high target of $641.00, reflecting varying levels of optimism among analysts. The consensus recommendation is "buy". Note: Analyst price targets are forward-looking estimates and not guarantees of future performance.
Vertex Pharmaceuticals Incorporated (VRTX) does not currently pay a regular dividend. The company may be reinvesting profits into growth initiatives, or may not yet be profitable enough to distribute earnings to shareholders.
Key risks for Vertex Pharmaceuticals Incorporated (VRTX) investors include: 1. Moderate volatility (30.9% annualized)—price swings are notable. 2. Broader market and macroeconomic risks (interest rates, inflation, geopolitical events). 3. Biotechnology sector-specific competitive pressures. Investors should diversify and consider their risk tolerance before investing.
Here is Vertex Pharmaceuticals Incorporated's (VRTX) current debt and financial health profile: Total debt stands at $1.99B. The debt-to-equity ratio is 10.26, which is conservative and indicates a strong balance sheet with low leverage. The current ratio is 3.02, indicating strong short-term liquidity. The quick ratio is 2.38. The company holds $7.25B in cash and equivalents. Free cash flow is positive at $2.78B, providing a cushion for debt servicing and shareholder returns.